US · Healthcare · Biotechnology
EPS came in at -1.20 against a street estimate of -0.93 — a miss of 29.0%.
Analysts rate Palvella Therapeutics, Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $229.60.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 8.05% |
| First Light Asset Management, LLC | 6.85% |
| Bvf Inc | 6.71% |
| Frazier Life Sciences Management, L.P. | 6.16% |
| BlackRock Inc | 4.80% |
| Jennison Associates LLC | 4.47% |
| Vanguard Capital Management, LLC | 3.33% |
| State Street Corp | 3.20% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 | 2026-07-14 |
| Board / officer change · Q2 2026 | 2026-06-30 |
| Board / officer change · Q2 2026 | 2026-06-16 |
| Company announcement · Q2 2026 | 2026-05-20 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-30 |
| Annual report FY2025 | 2026-03-31 |
| Quarterly report · Q3 2025 | 2025-11-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Palvella Therapeutics, Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.